ATRA (Atara Bio) Enterprise Value-to-Revenue Coefficient

Atara Biotherapeutics (ATRA) is facing a liquidity shortage, reducing headcount to preserve resources for priority projects. The price-to-sales multiple trend visualizes the current asset valuation, where the value 26492.42 reflects the metric's balance. Revenues are based on the implementation of T-cell therapy, with the primary financial momentum expected from the commercialization of Ebvallo for the treatment of post-organ transplant complications.
Financial and market metric breakdowns for Atara Bio (ATRA)

Under the leadership of Pascal Touchon, Atara Biotherapeutics (ATRA) is restructuring its operational processes to align with a partner-based commercialization model for T-cell products. The dynamics of the company's enterprise value-to-revenue ratio reflect the relationship between enterprise value (EV) and sales volume, excluding the impact of debt load, which allows investors to assess the fundamental overvaluation of the asset amid current subdued market expectations.